Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Fineline Cube Jul 2, 2026
Company Deals Digital

Insilico Medicine and Takeda Launch $600M Strategic AI Drug Discovery Collaboration – Pharma.AI Platform to Drive Candidate Identification for High-Potential Therapeutic Targets

Fineline Cube Jul 2, 2026
Company Deals

Nona Biosciences and Lonza Forge Strategic Alliance to Develop Best-in-Class Blood-Brain Barrier Penetration Technology for CNS Therapeutics

Fineline Cube Jul 2, 2026
Company Deals

Ipsen to Acquire Memo Therapeutics for €200M Plus Milestones, Gaining Phase II BK Virus Antibody Potravitug for Transplant Nephropathy

Fineline Cube Jul 2, 2026
Company Deals

Ribo Life Science Achieves First Milestone in siRNA Collaboration with Madrigal for MASH Therapeutics

Fineline Cube Jul 2, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Bio-sincerity Secures NMPA Clinical Trial Approval for BIOS0629-109, Novel XPO1 Inhibitor for Advanced Malignant Tumors

Fineline Cube Jul 3, 2026
Company Drug

Novartis Secures EU Approval for Itvisma, First Gene Replacement Therapy for Broad SMA Population Including Patients Two Years and Older

Fineline Cube Jul 3, 2026
Company Deals

PharmaEssentia Announces Licensing Agreement with WuXi Biologics for Antibody Development

Fineline Cube Oct 7, 2023

Taiwan-based PharmaEssentia Corporation (TPE: 6446, FRA: 8Z1) has entered into a licensing agreement with China’s...

Company Deals

Boehringer Ingelheim Collaborates with Zeiss Medical Technology on Retinal Disease Detection

Fineline Cube Oct 7, 2023

Germany’s Boehringer Ingelheim (BI) has entered into a collaboration agreement with fellow German firm Zeiss...

Policy / Regulatory

Guangdong Medicine Exchange Announces Volume-Based Procurement for Medical Devices

Fineline Cube Oct 7, 2023

The Guangdong Medicine Exchange has issued three notifications regarding the volume-based procurement (VBP) of medical...

Deals Medical Device

Cardinal Health Acquires MedAlliance for $1.135 Billion to Enhance Vascular Intervention Portfolio

Fineline Cube Oct 7, 2023

US-based Cardinal Health (NYSE: CAH) has announced the acquisition of Swiss firm MedAlliance for a...

Company Deals

Hong Kong Government Partners with AstraZeneca, Tigermed, and Simcere to Boost Innovation

Fineline Cube Oct 7, 2023

The government of the Hong Kong Special Administrative Region has entered into significant partnership agreements...

Company Drug

Everest Medicines and Calliditas Present New Data on Nefecon for IgA Nephropathy

Fineline Cube Oct 7, 2023

Everest Medicines (HKG: 1952), in partnership with Calliditas Therapeutics AB (Nasdaq: CALT), recently presented new...

Company Drug

Zhaoke Ophthalmology Completes Patient Enrollment for Phase III Trials of TAB014 and Epinastine

Fineline Cube Oct 7, 2023

Zhaoke Ophthalmology Ltd (HKG: 6622), a former subsidiary of Lee’s Pharmaceutical Holdings Ltd (HKG: 0950),...

Company Drug

Amicus Therapeutics Secures FDA Approval for Pombiliti and Opfolda Combination Therapy

Fineline Cube Oct 7, 2023

Amicus Therapeutics (NASDAQ: FOLD), headquartered in the United States, has announced that it has received...

Company Deals

Vela Diagnostics Partners with SRL Inc. to Expand Molecular Diagnostics in Japan

Fineline Cube Oct 7, 2023

Singapore-based Vela Diagnostics, a global leader in integrated molecular solutions for diagnosing infectious diseases and...

Company Drug

Transcenta Secures FDA Approval for Phase III Trial of Osemitamab

Fineline Cube Oct 7, 2023

China-based Transcenta Holding Ltd (HKG: 6628) has announced that it has received approval from the...

Policy / Regulatory

Shanghai Boosts Community Healthcare with Enhanced Reimbursement and Services

Fineline Cube Sep 28, 2023

Shanghai’s healthcare security administration has announced a comprehensive set of measures aimed at enhancing community...

Company Deals

Novo Nordisk and Evotec Launch LAB eN² to Accelerate Drug Discovery for Rare Diseases

Fineline Cube Sep 28, 2023

Global healthcare company Novo Nordisk (NYSE: NVO) and drug discovery alliance Evotec (NASDAQ: EVO) have...

Company Deals

Roche Secures Global Rights to Ionis Pharmaceuticals’ Alzheimer’s and Huntington’s Disease Candidates

Fineline Cube Sep 28, 2023

Swiss pharmaceutical giant Roche (SWX: ROG) has announced the acquisition of global rights to develop,...

Company Drug

Takeda Receives FDA Approval for Subcutaneous Entyvio as UC Maintenance Therapy

Fineline Cube Sep 28, 2023

The US Food and Drug Administration (FDA) has granted Japan’s Takeda Pharmaceuticals (TYO: 4502) regulatory...

Company Medical Device

Neusoft Medical’s NeuRT Aurora Receives NMPA Approval for Advanced Radiotherapy Platform

Fineline Cube Sep 28, 2023

Neusoft Medical Systems Co., Ltd, a leading player in the medical technology sector, has announced...

Company Medical Device

CStone Pharmaceuticals’ PDGFRA Mutation Detection Kit Receives NMPA Approval

Fineline Cube Sep 28, 2023

CStone Pharmaceuticals (HKG: 2616), a China-based biopharmaceutical company, has announced that it has received marketing...

Company Deals

RemeGen and Akeso Biopharma Initiate Phase II Study for Gastric Cancer Combo Therapy

Fineline Cube Sep 28, 2023

China-based RemeGen Ltd (HKG: 9995) is poised to conduct a Phase II clinical study in...

Company Drug

Eli Lilly’s Insulin Biosimilar YouBiAn Approved for Diabetes Treatment in China

Fineline Cube Sep 28, 2023

US pharmaceutical major Eli Lilly (NYSE: LLY) has announced that it has received market approval...

Company Drug

Everest Medicines’ Xerava Receives Marketing Approval from TFDA for cIAI Treatment

Fineline Cube Sep 28, 2023

Everest Medicines (HKG: 1952) has announced that it has received marketing approval for its antibiotic...

Company Medical Device

Sino Medical Sciences Receives Turkish Approval for HT Supreme Drug-Eluting Stent System

Fineline Cube Sep 28, 2023

Sino Medical Sciences Technology Inc., (SHA: 688108), a leading Chinese medical device company, has announced...

Posts pagination

1 … 489 490 491 … 690

Recent updates

  • Bio-sincerity Secures NMPA Clinical Trial Approval for BIOS0629-109, Novel XPO1 Inhibitor for Advanced Malignant Tumors
  • Novartis Secures EU Approval for Itvisma, First Gene Replacement Therapy for Broad SMA Population Including Patients Two Years and Older
  • Ocumension Therapeutics Secures NMPA Approval for OT-502, China’s First Single-Dose Sustained-Release Intraocular Steroid for Postoperative Inflammation
  • Hotgen Biotech Launches AI Subsidiary to Transform Small Nucleic Acid Drug Discovery
  • Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Bio-sincerity Secures NMPA Clinical Trial Approval for BIOS0629-109, Novel XPO1 Inhibitor for Advanced Malignant Tumors

Company Drug

Novartis Secures EU Approval for Itvisma, First Gene Replacement Therapy for Broad SMA Population Including Patients Two Years and Older

Company Drug

Ocumension Therapeutics Secures NMPA Approval for OT-502, China’s First Single-Dose Sustained-Release Intraocular Steroid for Postoperative Inflammation

Company

Hotgen Biotech Launches AI Subsidiary to Transform Small Nucleic Acid Drug Discovery

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.